Neurol. pro Praxi, 2002; 3: 156-159

Tardivní dyskineze - patofyziologie a klinické projevy

MUDr. Klára Látalová, doc. MUDr. Vladimír Pidrman Ph.D, prof. MUDr. Jaroslav Bouček CSc
Psychiatrická klinika FN a LF UP, Olomouc

Keywords: tardivní dyskineze, neuroleptika, antipsychotika, extrapyramidové příznaky, dopamin, serotonin # GABA.

Published: December 31, 2002  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Látalová K, Pidrman V, Bouček J. Tardivní dyskineze - patofyziologie a klinické projevy. Neurol. praxi. 2002;3(3):156-159.

Tardivní dyskineze je mimovolní pohybová porucha vznikající nejčastěji při dlouhodobé léčbě klasickými neuroleptiky. Vzácněji může vzniknout spontánně, v průběhu psychotického onemocnění nebo být nepříjemným doprovodným příznakem některých somatických poruch (např. hormonálních, autoimunních). Tardivní dyskineze se klinicky projevuje abnormními choreiformními, atetoidními a balistikými pohyby rukou, nohou, trupu a především grimasováním v obličeji, žvýkáním, špulením či rytmickou protruzí jazyka. Pacientovo okolí vnímá tyto pohyby jako neúčelné, směšné či schválně přehráváné. Tardivní dyskienze pacienty sociálně omezuje a může přispívat ke zhoršení compliance, tím i k celkovému neúspěchu léčby.

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Adler LA, Edson R, Lavori P, et al. Long-term treatmant effects of vitamin E for tardive dyskinesia. Biol Psychiatry 1998; 43: 868-872. Go to original source... Go to PubMed...
    2. Bleuler E. Dementia praecox or the Group of Schizophrenia, New york, Ny: International Universities Press; 1950.
    3. Burnes TRE, Braude WM. Akathisia variants and tardive dyskinesia. Arch Gen Psychiatry 1985; 542: 874-878. Go to original source... Go to PubMed...
    4. Casey DE. Tardive dyskinesia: animal models. Psychopharmacol Bull 1984; 20: 376-379. Go to PubMed...
    5. Casey DE. Spontaneous and tardive dyskinesia: Clinical and laboratory studies. J Clin Psychiatry 1985; 46-47.
    6. Fahn S, Eldridge R. Definition od dystonia and classification of the dystonic state. Adv Neurol 1997; 14: 1-5.
    7. Faurbye A, Rash PJ, Peterson PB, et al. Neurological symptoms in pharmakotherapy of psychoses. Acta Psychiatrices Scandinavica, 1964; 40: 10-27. Go to original source... Go to PubMed...
    8. Fenton WS, Wyatt RJ, et al. Prevalence of spontaneous dyskinesia in schizophrenic and non-schizophrenic psychyatric patients. Br J Psychiatry 1997; 171: 265-268. Go to original source... Go to PubMed...
    9. Fibiger HC, Loyd KG. Neurobiological substrates of tardive dyskinesia: the GABA hypothesis. Trend Neuroscience 1984; 7: 462-464. Go to original source...
    10. Fish F. Leonards Classification of Schizophrenia. J Ment Sci 1958; 104: 943-947. Go to original source... Go to PubMed...
    11. Glazer WM. Expected incidence of tardive dyskinesia associated with atypical antipsychotics. J Clin Psychiatry 2000; 6 (Supl 4): 21-26.
    12. Gune LM, Andersson U, Bondenson U, et al. Spontaneous chewing movements in rats during acute and chronic antipsychotic drug administration. Pharmacol Biochem Behav 1986; 25: 897-901. Go to original source... Go to PubMed...
    13. Gunne LM, Barany S. Haloperidole-induced tardive dyskinesia in monkeys. Psychopharmacology 1976; 50: 237-240. Go to original source... Go to PubMed...
    14. Gunne LM, Haggstrom JE, Sjoguist B. Associatin with persistent neuroleptic-induced dyskinesia of regional changes in brain GABA synthesis. Nature 1984; 309: 347-349. Go to original source... Go to PubMed...
    15. Hoffman WF, Casey DE. Computer tomographic evaluation of patients with tardive dyskinesia. Schizoph Res 1991; 5: 1-12. Go to original source... Go to PubMed...
    16. Chattterjee A, Chakos M, Koreen A, et al. Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients. Am J Psychiatry 1995; 152: 1724-1729. Go to original source... Go to PubMed...
    17. Chouinard G, et al. Factors related to tardive dyskinesia. Am J Psychiatry 1979; 136: 79-82. Go to original source... Go to PubMed...
    18. Jeste DV, Caligiuru MP, Paulsen JS, at al. Risk of tardive dyskinesia in older patient: a prospective lingitudila studiy of 266 patients. Arch Gen Psychiatry 1995; 52: 756-765. Go to original source... Go to PubMed...
    19. Kerk PE, McElroy SL, Strakowski SM. Anticonvulsats and antipsychotics in the treatment of bipolar disorder. J Clin Psychiatry 1998; 59 (Supl 6): 74-81.
    20. Kraepelin E. Dementia praecox and Paraphrenia, Edinburg, Scotland: E&S Livingstone; 1919.
    21. Morgenstern H, Glazer WM, Niedzwiecki D, et al. The impact of neuroleptic medication on tardive dyskinesia: a meta-analysis of published studies. Am J Public Health 1987; 77: 717-724. Go to original source... Go to PubMed...
    22. Owens DGJ, Johnstone EC, Frith CD. Spontaneous involutery disorders of movement: their prevalence, severity, and distribution in chronic schizophrenics with and without trearment with neuroleptics. Arch Gen Psychiatry 1982; 39: 452-461. Go to original source... Go to PubMed...
    23. Rupniak NMJ, Jenner P, Marsden CD. Cholinergic manipulation of perioral behavior induced by chronic neuroleptic administration to rats. Psychopharmacology 1983; 79: 226-240. Go to original source... Go to PubMed...
    24. Schonecker M. Reseach diagnosis for tardive dyskinesia Arch Gen Psychiatry 1957; 39: 486-487. Go to original source... Go to PubMed...
    25. Sigweld J, Bouttier D, Raymond C, et al. Quatre cas de dyskinesie facio-bucco-lingou-masticatice a evalution prolonge secondaire a un traitment par les neuroleptiques. Revue Neurologique 1959; 100: 751-755. Go to PubMed...
    26. Simpson GM, Jaffe ME. Reduciton of tardive dystonia with olanzapine. Am J Psychiatry 2000; 42: 852-900.

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.